Global Neuromyelitis Optica Drug

Neuromyelitis Optica Drug Comprehensive Study by Type (Glucocorticoids, Immunoglobulin), Application (Acute Attack, Remission Prophylactic treatment), Product Type (Production Share, Price Rage, Cost) Players and Region - Global Market Outlook to 2030

Neuromyelitis Optica Drug Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Neuromyelitis Optica Drug
Neuromyelitis Optica (NMO), an autoimmune demyelinating disease, also called neuromyelitis optica spectrum disorders (NMOSD) and axonal damage predominantly targeting optic nerves and spinal cord. NMO treatment involves therapies to reverse recent symptoms and prevent future attacks. On the other hand, Neuromyelitis optica can't be cured, though long-term remission and may be possible with the right management. Owing to increasing incidences of paralysis in the legs or arms, painful spasms, loss of sensation, uncontrollable vomiting, and hiccups, and bladder or bowel dysfunction from spinal cord damage, the neuromyelitis optica drug, and therapy market is growing across the world.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that Global Vendors will contribute the maximum growth to Global Neuromyelitis Optica Drug market throughout the forecasted period. Established and emerging Vendors should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (Germany), FRESENIUS (United States), TEVA (Israel), SANDOZ (Germany), Intas (Ahmedabad), Gyjtrs (United States), NANG KUANG (China), Tianjin Kingyork (China), Baxter (United States) and CSL (Australia) are some of the key players that are part of study coverage. Additionally, the Vendors which are also part of the research coverage are Grifols (Spain), Octapharma (Switzerland) and CBOP (Mumbai).

Segmentation Overview
AMA Research has segmented the market of Global Neuromyelitis Optica Drug market by Type (Glucocorticoids and Immunoglobulin), Application (Acute Attack and Remission Prophylactic treatment) and Region.



On the basis of geography, the market of Neuromyelitis Optica Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Product Type, the sub-segment i.e. Production Share will boost the Neuromyelitis Optica Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Adoption of Nano Technology in Neuromyelitis Optica Drug and Personalized Medicine and Customization for Consumers

Market Growth Drivers:
Emerging Countries of Neuromyelitis Optica Drug and Growing Market for Neuromyelitis Optica Drug

Challenges:
Increasing Investment and Strict Regulations

Restraints:
Implementation of Any Regulation Related to an Agitated Patient for drugs and Stringent International Quality Standards for Drugs

Opportunities:
Ability to Create New Technology and Innovative Drugs

Market Leaders and their expansionary development strategies
In December 2021, Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
October 30, 2019 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab (development code: SA237), an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD). EMA has granted Accelerated Assessment status for satralizumab.
The U.S. Food and Drug Administration (FDA) has also accepted the Biologics License Application (BLA) for satralizumab. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation and the FDA decision are expected in 2020.

Key Target Audience
Healthcare Industries, Pharmacists, Drugs Quality Analysts and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Glucocorticoids
  • Immunoglobulin
By Application
  • Acute Attack
  • Remission Prophylactic treatment
By Product Type
  • Production Share
  • Price Rage
  • Cost

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Emerging Countries of Neuromyelitis Optica Drug
      • 3.2.2. Growing Market for Neuromyelitis Optica Drug
    • 3.3. Market Challenges
      • 3.3.1. Increasing Investment and Strict Regulations
    • 3.4. Market Trends
      • 3.4.1. Adoption of Nano Technology in Neuromyelitis Optica Drug
      • 3.4.2. Personalized Medicine and Customization for Consumers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neuromyelitis Optica Drug, by Type, Application, Product Type and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Neuromyelitis Optica Drug (Value)
      • 5.2.1. Global Neuromyelitis Optica Drug by: Type (Value)
        • 5.2.1.1. Glucocorticoids
        • 5.2.1.2. Immunoglobulin
      • 5.2.2. Global Neuromyelitis Optica Drug by: Application (Value)
        • 5.2.2.1. Acute Attack
        • 5.2.2.2. Remission Prophylactic treatment
      • 5.2.3. Global Neuromyelitis Optica Drug by: Type (Value)
        • 5.2.3.1. Glucocorticoids
        • 5.2.3.2. Immunoglobulin
      • 5.2.4. Global Neuromyelitis Optica Drug by: Product Type (Value)
        • 5.2.4.1. Production Share
        • 5.2.4.2. Price Rage
        • 5.2.4.3. Cost
      • 5.2.5. Global Neuromyelitis Optica Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Neuromyelitis Optica Drug (Volume)
      • 5.3.1. Global Neuromyelitis Optica Drug by: Type (Volume)
        • 5.3.1.1. Glucocorticoids
        • 5.3.1.2. Immunoglobulin
      • 5.3.2. Global Neuromyelitis Optica Drug by: Application (Volume)
        • 5.3.2.1. Acute Attack
        • 5.3.2.2. Remission Prophylactic treatment
      • 5.3.3. Global Neuromyelitis Optica Drug by: Type (Volume)
        • 5.3.3.1. Glucocorticoids
        • 5.3.3.2. Immunoglobulin
      • 5.3.4. Global Neuromyelitis Optica Drug by: Product Type (Volume)
        • 5.3.4.1. Production Share
        • 5.3.4.2. Price Rage
        • 5.3.4.3. Cost
      • 5.3.5. Global Neuromyelitis Optica Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Neuromyelitis Optica Drug (Price)
      • 5.4.1. Global Neuromyelitis Optica Drug by: Type (Price)
  • 6. Neuromyelitis Optica Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. FRESENIUS (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. TEVA (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. SANDOZ (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Intas (Ahmedabad)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gyjtrs (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. NANG KUANG (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Tianjin Kingyork (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baxter (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CSL (Australia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neuromyelitis Optica Drug Sale, by Type, Application, Product Type and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Neuromyelitis Optica Drug (Value)
      • 7.2.1. Global Neuromyelitis Optica Drug by: Type (Value)
        • 7.2.1.1. Glucocorticoids
        • 7.2.1.2. Immunoglobulin
      • 7.2.2. Global Neuromyelitis Optica Drug by: Application (Value)
        • 7.2.2.1. Acute Attack
        • 7.2.2.2. Remission Prophylactic treatment
      • 7.2.3. Global Neuromyelitis Optica Drug by: Type (Value)
        • 7.2.3.1. Glucocorticoids
        • 7.2.3.2. Immunoglobulin
      • 7.2.4. Global Neuromyelitis Optica Drug by: Product Type (Value)
        • 7.2.4.1. Production Share
        • 7.2.4.2. Price Rage
        • 7.2.4.3. Cost
      • 7.2.5. Global Neuromyelitis Optica Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Neuromyelitis Optica Drug (Volume)
      • 7.3.1. Global Neuromyelitis Optica Drug by: Type (Volume)
        • 7.3.1.1. Glucocorticoids
        • 7.3.1.2. Immunoglobulin
      • 7.3.2. Global Neuromyelitis Optica Drug by: Application (Volume)
        • 7.3.2.1. Acute Attack
        • 7.3.2.2. Remission Prophylactic treatment
      • 7.3.3. Global Neuromyelitis Optica Drug by: Type (Volume)
        • 7.3.3.1. Glucocorticoids
        • 7.3.3.2. Immunoglobulin
      • 7.3.4. Global Neuromyelitis Optica Drug by: Product Type (Volume)
        • 7.3.4.1. Production Share
        • 7.3.4.2. Price Rage
        • 7.3.4.3. Cost
      • 7.3.5. Global Neuromyelitis Optica Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Neuromyelitis Optica Drug (Price)
      • 7.4.1. Global Neuromyelitis Optica Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuromyelitis Optica Drug: by Type(USD Million)
  • Table 2. Neuromyelitis Optica Drug Glucocorticoids , by Region USD Million (2018-2023)
  • Table 3. Neuromyelitis Optica Drug Immunoglobulin , by Region USD Million (2018-2023)
  • Table 4. Neuromyelitis Optica Drug: by Application(USD Million)
  • Table 5. Neuromyelitis Optica Drug Acute Attack , by Region USD Million (2018-2023)
  • Table 6. Neuromyelitis Optica Drug Remission Prophylactic treatment , by Region USD Million (2018-2023)
  • Table 7. Neuromyelitis Optica Drug: by Type(USD Million)
  • Table 8. Neuromyelitis Optica Drug Glucocorticoids , by Region USD Million (2018-2023)
  • Table 9. Neuromyelitis Optica Drug Immunoglobulin , by Region USD Million (2018-2023)
  • Table 10. Neuromyelitis Optica Drug: by Product Type(USD Million)
  • Table 11. Neuromyelitis Optica Drug Production Share , by Region USD Million (2018-2023)
  • Table 12. Neuromyelitis Optica Drug Price Rage , by Region USD Million (2018-2023)
  • Table 13. Neuromyelitis Optica Drug Cost , by Region USD Million (2018-2023)
  • Table 14. South America Neuromyelitis Optica Drug, by Country USD Million (2018-2023)
  • Table 15. South America Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 16. South America Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 17. South America Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 18. Brazil Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 19. Brazil Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 20. Brazil Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 21. Argentina Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 22. Argentina Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 23. Argentina Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 24. Rest of South America Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 27. Asia Pacific Neuromyelitis Optica Drug, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 31. China Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 32. China Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 33. China Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 34. Japan Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 35. Japan Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 36. Japan Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 37. India Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 38. India Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 39. India Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 40. South Korea Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 41. South Korea Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 42. South Korea Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 43. Taiwan Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 44. Taiwan Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 45. Taiwan Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 46. Australia Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 47. Australia Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 48. Australia Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 52. Europe Neuromyelitis Optica Drug, by Country USD Million (2018-2023)
  • Table 53. Europe Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 54. Europe Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 55. Europe Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 56. Germany Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 57. Germany Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 58. Germany Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 59. France Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 60. France Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 61. France Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 62. Italy Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 63. Italy Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 64. Italy Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 65. United Kingdom Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 68. Netherlands Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 69. Netherlands Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 70. Netherlands Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 71. Rest of Europe Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 74. MEA Neuromyelitis Optica Drug, by Country USD Million (2018-2023)
  • Table 75. MEA Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 76. MEA Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 77. MEA Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 78. Middle East Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 79. Middle East Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 80. Middle East Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 81. Africa Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 82. Africa Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 83. Africa Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 84. North America Neuromyelitis Optica Drug, by Country USD Million (2018-2023)
  • Table 85. North America Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 86. North America Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 87. North America Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 88. United States Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 89. United States Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 90. United States Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 91. Canada Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 92. Canada Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 93. Canada Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 94. Mexico Neuromyelitis Optica Drug, by Type USD Million (2018-2023)
  • Table 95. Mexico Neuromyelitis Optica Drug, by Application USD Million (2018-2023)
  • Table 96. Mexico Neuromyelitis Optica Drug, by Product Type USD Million (2018-2023)
  • Table 97. Neuromyelitis Optica Drug Sales: by Type(Unit)
  • Table 98. Neuromyelitis Optica Drug Sales Glucocorticoids , by Region Unit (2018-2023)
  • Table 99. Neuromyelitis Optica Drug Sales Immunoglobulin , by Region Unit (2018-2023)
  • Table 100. Neuromyelitis Optica Drug Sales: by Application(Unit)
  • Table 101. Neuromyelitis Optica Drug Sales Acute Attack , by Region Unit (2018-2023)
  • Table 102. Neuromyelitis Optica Drug Sales Remission Prophylactic treatment , by Region Unit (2018-2023)
  • Table 103. Neuromyelitis Optica Drug Sales: by Type(Unit)
  • Table 104. Neuromyelitis Optica Drug Sales Glucocorticoids , by Region Unit (2018-2023)
  • Table 105. Neuromyelitis Optica Drug Sales Immunoglobulin , by Region Unit (2018-2023)
  • Table 106. Neuromyelitis Optica Drug Sales: by Product Type(Unit)
  • Table 107. Neuromyelitis Optica Drug Sales Production Share , by Region Unit (2018-2023)
  • Table 108. Neuromyelitis Optica Drug Sales Price Rage , by Region Unit (2018-2023)
  • Table 109. Neuromyelitis Optica Drug Sales Cost , by Region Unit (2018-2023)
  • Table 110. South America Neuromyelitis Optica Drug Sales, by Country Unit (2018-2023)
  • Table 111. South America Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 112. South America Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 113. South America Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 114. Brazil Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 115. Brazil Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 116. Brazil Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 117. Argentina Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 118. Argentina Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 119. Argentina Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 120. Rest of South America Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 121. Rest of South America Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 122. Rest of South America Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 123. Asia Pacific Neuromyelitis Optica Drug Sales, by Country Unit (2018-2023)
  • Table 124. Asia Pacific Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 125. Asia Pacific Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 126. Asia Pacific Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 127. China Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 128. China Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 129. China Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 130. Japan Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 131. Japan Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 132. Japan Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 133. India Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 134. India Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 135. India Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 136. South Korea Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 137. South Korea Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 138. South Korea Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 139. Taiwan Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 140. Taiwan Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 141. Taiwan Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 142. Australia Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 143. Australia Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 144. Australia Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 145. Rest of Asia-Pacific Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 146. Rest of Asia-Pacific Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 147. Rest of Asia-Pacific Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 148. Europe Neuromyelitis Optica Drug Sales, by Country Unit (2018-2023)
  • Table 149. Europe Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 150. Europe Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 151. Europe Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 152. Germany Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 153. Germany Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 154. Germany Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 155. France Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 156. France Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 157. France Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 158. Italy Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 159. Italy Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 160. Italy Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 161. United Kingdom Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 162. United Kingdom Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 163. United Kingdom Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 164. Netherlands Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 165. Netherlands Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 166. Netherlands Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 167. Rest of Europe Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 168. Rest of Europe Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 169. Rest of Europe Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 170. MEA Neuromyelitis Optica Drug Sales, by Country Unit (2018-2023)
  • Table 171. MEA Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 172. MEA Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 173. MEA Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 174. Middle East Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 175. Middle East Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 176. Middle East Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 177. Africa Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 178. Africa Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 179. Africa Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 180. North America Neuromyelitis Optica Drug Sales, by Country Unit (2018-2023)
  • Table 181. North America Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 182. North America Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 183. North America Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 184. United States Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 185. United States Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 186. United States Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 187. Canada Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 188. Canada Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 189. Canada Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 190. Mexico Neuromyelitis Optica Drug Sales, by Type Unit (2018-2023)
  • Table 191. Mexico Neuromyelitis Optica Drug Sales, by Application Unit (2018-2023)
  • Table 192. Mexico Neuromyelitis Optica Drug Sales, by Product Type Unit (2018-2023)
  • Table 193. Neuromyelitis Optica Drug: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Neuromyelitis Optica Drug: by Type(USD Million)
  • Table 205. Neuromyelitis Optica Drug Glucocorticoids , by Region USD Million (2025-2030)
  • Table 206. Neuromyelitis Optica Drug Immunoglobulin , by Region USD Million (2025-2030)
  • Table 207. Neuromyelitis Optica Drug: by Application(USD Million)
  • Table 208. Neuromyelitis Optica Drug Acute Attack , by Region USD Million (2025-2030)
  • Table 209. Neuromyelitis Optica Drug Remission Prophylactic treatment , by Region USD Million (2025-2030)
  • Table 210. Neuromyelitis Optica Drug: by Type(USD Million)
  • Table 211. Neuromyelitis Optica Drug Glucocorticoids , by Region USD Million (2025-2030)
  • Table 212. Neuromyelitis Optica Drug Immunoglobulin , by Region USD Million (2025-2030)
  • Table 213. Neuromyelitis Optica Drug: by Product Type(USD Million)
  • Table 214. Neuromyelitis Optica Drug Production Share , by Region USD Million (2025-2030)
  • Table 215. Neuromyelitis Optica Drug Price Rage , by Region USD Million (2025-2030)
  • Table 216. Neuromyelitis Optica Drug Cost , by Region USD Million (2025-2030)
  • Table 217. South America Neuromyelitis Optica Drug, by Country USD Million (2025-2030)
  • Table 218. South America Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 219. South America Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 220. South America Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 221. Brazil Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 222. Brazil Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 223. Brazil Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 224. Argentina Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 225. Argentina Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 226. Argentina Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 227. Rest of South America Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 228. Rest of South America Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 229. Rest of South America Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 230. Asia Pacific Neuromyelitis Optica Drug, by Country USD Million (2025-2030)
  • Table 231. Asia Pacific Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 232. Asia Pacific Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 233. Asia Pacific Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 234. China Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 235. China Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 236. China Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 237. Japan Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 238. Japan Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 239. Japan Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 240. India Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 241. India Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 242. India Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 243. South Korea Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 244. South Korea Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 245. South Korea Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 246. Taiwan Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 247. Taiwan Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 248. Taiwan Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 249. Australia Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 250. Australia Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 251. Australia Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 255. Europe Neuromyelitis Optica Drug, by Country USD Million (2025-2030)
  • Table 256. Europe Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 257. Europe Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 258. Europe Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 259. Germany Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 260. Germany Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 261. Germany Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 262. France Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 263. France Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 264. France Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 265. Italy Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 266. Italy Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 267. Italy Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 268. United Kingdom Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 269. United Kingdom Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 270. United Kingdom Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 271. Netherlands Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 272. Netherlands Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 273. Netherlands Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 274. Rest of Europe Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 275. Rest of Europe Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 276. Rest of Europe Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 277. MEA Neuromyelitis Optica Drug, by Country USD Million (2025-2030)
  • Table 278. MEA Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 279. MEA Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 280. MEA Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 281. Middle East Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 282. Middle East Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 283. Middle East Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 284. Africa Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 285. Africa Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 286. Africa Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 287. North America Neuromyelitis Optica Drug, by Country USD Million (2025-2030)
  • Table 288. North America Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 289. North America Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 290. North America Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 291. United States Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 292. United States Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 293. United States Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 294. Canada Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 295. Canada Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 296. Canada Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 297. Mexico Neuromyelitis Optica Drug, by Type USD Million (2025-2030)
  • Table 298. Mexico Neuromyelitis Optica Drug, by Application USD Million (2025-2030)
  • Table 299. Mexico Neuromyelitis Optica Drug, by Product Type USD Million (2025-2030)
  • Table 300. Neuromyelitis Optica Drug Sales: by Type(Unit)
  • Table 301. Neuromyelitis Optica Drug Sales Glucocorticoids , by Region Unit (2025-2030)
  • Table 302. Neuromyelitis Optica Drug Sales Immunoglobulin , by Region Unit (2025-2030)
  • Table 303. Neuromyelitis Optica Drug Sales: by Application(Unit)
  • Table 304. Neuromyelitis Optica Drug Sales Acute Attack , by Region Unit (2025-2030)
  • Table 305. Neuromyelitis Optica Drug Sales Remission Prophylactic treatment , by Region Unit (2025-2030)
  • Table 306. Neuromyelitis Optica Drug Sales: by Type(Unit)
  • Table 307. Neuromyelitis Optica Drug Sales Glucocorticoids , by Region Unit (2025-2030)
  • Table 308. Neuromyelitis Optica Drug Sales Immunoglobulin , by Region Unit (2025-2030)
  • Table 309. Neuromyelitis Optica Drug Sales: by Product Type(Unit)
  • Table 310. Neuromyelitis Optica Drug Sales Production Share , by Region Unit (2025-2030)
  • Table 311. Neuromyelitis Optica Drug Sales Price Rage , by Region Unit (2025-2030)
  • Table 312. Neuromyelitis Optica Drug Sales Cost , by Region Unit (2025-2030)
  • Table 313. South America Neuromyelitis Optica Drug Sales, by Country Unit (2025-2030)
  • Table 314. South America Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 315. South America Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 316. South America Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 317. Brazil Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 318. Brazil Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 319. Brazil Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 320. Argentina Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 321. Argentina Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 322. Argentina Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 323. Rest of South America Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 324. Rest of South America Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 325. Rest of South America Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 326. Asia Pacific Neuromyelitis Optica Drug Sales, by Country Unit (2025-2030)
  • Table 327. Asia Pacific Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 328. Asia Pacific Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 329. Asia Pacific Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 330. China Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 331. China Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 332. China Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 333. Japan Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 334. Japan Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 335. Japan Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 336. India Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 337. India Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 338. India Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 339. South Korea Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 340. South Korea Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 341. South Korea Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 342. Taiwan Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 343. Taiwan Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 344. Taiwan Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 345. Australia Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 346. Australia Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 347. Australia Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 348. Rest of Asia-Pacific Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 349. Rest of Asia-Pacific Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 350. Rest of Asia-Pacific Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 351. Europe Neuromyelitis Optica Drug Sales, by Country Unit (2025-2030)
  • Table 352. Europe Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 353. Europe Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 354. Europe Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 355. Germany Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 356. Germany Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 357. Germany Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 358. France Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 359. France Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 360. France Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 361. Italy Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 362. Italy Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 363. Italy Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 364. United Kingdom Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 365. United Kingdom Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 366. United Kingdom Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 367. Netherlands Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 368. Netherlands Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 369. Netherlands Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 370. Rest of Europe Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 371. Rest of Europe Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 372. Rest of Europe Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 373. MEA Neuromyelitis Optica Drug Sales, by Country Unit (2025-2030)
  • Table 374. MEA Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 375. MEA Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 376. MEA Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 377. Middle East Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 378. Middle East Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 379. Middle East Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 380. Africa Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 381. Africa Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 382. Africa Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 383. North America Neuromyelitis Optica Drug Sales, by Country Unit (2025-2030)
  • Table 384. North America Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 385. North America Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 386. North America Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 387. United States Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 388. United States Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 389. United States Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 390. Canada Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 391. Canada Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 392. Canada Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 393. Mexico Neuromyelitis Optica Drug Sales, by Type Unit (2025-2030)
  • Table 394. Mexico Neuromyelitis Optica Drug Sales, by Application Unit (2025-2030)
  • Table 395. Mexico Neuromyelitis Optica Drug Sales, by Product Type Unit (2025-2030)
  • Table 396. Neuromyelitis Optica Drug: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neuromyelitis Optica Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Neuromyelitis Optica Drug: by Application USD Million (2018-2023)
  • Figure 6. Global Neuromyelitis Optica Drug: by Type USD Million (2018-2023)
  • Figure 7. Global Neuromyelitis Optica Drug: by Product Type USD Million (2018-2023)
  • Figure 8. South America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 9. Asia Pacific Neuromyelitis Optica Drug Share (%), by Country
  • Figure 10. Europe Neuromyelitis Optica Drug Share (%), by Country
  • Figure 11. MEA Neuromyelitis Optica Drug Share (%), by Country
  • Figure 12. North America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 13. Global Neuromyelitis Optica Drug: by Type Unit (2018-2023)
  • Figure 14. Global Neuromyelitis Optica Drug: by Application Unit (2018-2023)
  • Figure 15. Global Neuromyelitis Optica Drug: by Type Unit (2018-2023)
  • Figure 16. Global Neuromyelitis Optica Drug: by Product Type Unit (2018-2023)
  • Figure 17. South America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 18. Asia Pacific Neuromyelitis Optica Drug Share (%), by Country
  • Figure 19. Europe Neuromyelitis Optica Drug Share (%), by Country
  • Figure 20. MEA Neuromyelitis Optica Drug Share (%), by Country
  • Figure 21. North America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 22. Global Neuromyelitis Optica Drug: by Type USD/Units (2018-2023)
  • Figure 23. Global Neuromyelitis Optica Drug share by Players 2023 (%)
  • Figure 24. Global Neuromyelitis Optica Drug share by Players (Top 3) 2023(%)
  • Figure 25. Global Neuromyelitis Optica Drug share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Pfizer (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (Germany) Revenue: by Geography 2023
  • Figure 29. FRESENIUS (United States) Revenue, Net Income and Gross profit
  • Figure 30. FRESENIUS (United States) Revenue: by Geography 2023
  • Figure 31. TEVA (Israel) Revenue, Net Income and Gross profit
  • Figure 32. TEVA (Israel) Revenue: by Geography 2023
  • Figure 33. SANDOZ (Germany) Revenue, Net Income and Gross profit
  • Figure 34. SANDOZ (Germany) Revenue: by Geography 2023
  • Figure 35. Intas (Ahmedabad) Revenue, Net Income and Gross profit
  • Figure 36. Intas (Ahmedabad) Revenue: by Geography 2023
  • Figure 37. Gyjtrs (United States) Revenue, Net Income and Gross profit
  • Figure 38. Gyjtrs (United States) Revenue: by Geography 2023
  • Figure 39. NANG KUANG (China) Revenue, Net Income and Gross profit
  • Figure 40. NANG KUANG (China) Revenue: by Geography 2023
  • Figure 41. Tianjin Kingyork (China) Revenue, Net Income and Gross profit
  • Figure 42. Tianjin Kingyork (China) Revenue: by Geography 2023
  • Figure 43. Baxter (United States) Revenue, Net Income and Gross profit
  • Figure 44. Baxter (United States) Revenue: by Geography 2023
  • Figure 45. CSL (Australia) Revenue, Net Income and Gross profit
  • Figure 46. CSL (Australia) Revenue: by Geography 2023
  • Figure 47. Global Neuromyelitis Optica Drug: by Type USD Million (2025-2030)
  • Figure 48. Global Neuromyelitis Optica Drug: by Application USD Million (2025-2030)
  • Figure 49. Global Neuromyelitis Optica Drug: by Type USD Million (2025-2030)
  • Figure 50. Global Neuromyelitis Optica Drug: by Product Type USD Million (2025-2030)
  • Figure 51. South America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 52. Asia Pacific Neuromyelitis Optica Drug Share (%), by Country
  • Figure 53. Europe Neuromyelitis Optica Drug Share (%), by Country
  • Figure 54. MEA Neuromyelitis Optica Drug Share (%), by Country
  • Figure 55. North America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 56. Global Neuromyelitis Optica Drug: by Type Unit (2025-2030)
  • Figure 57. Global Neuromyelitis Optica Drug: by Application Unit (2025-2030)
  • Figure 58. Global Neuromyelitis Optica Drug: by Type Unit (2025-2030)
  • Figure 59. Global Neuromyelitis Optica Drug: by Product Type Unit (2025-2030)
  • Figure 60. South America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 61. Asia Pacific Neuromyelitis Optica Drug Share (%), by Country
  • Figure 62. Europe Neuromyelitis Optica Drug Share (%), by Country
  • Figure 63. MEA Neuromyelitis Optica Drug Share (%), by Country
  • Figure 64. North America Neuromyelitis Optica Drug Share (%), by Country
  • Figure 65. Global Neuromyelitis Optica Drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer (Germany)
  • FRESENIUS (United States)
  • TEVA (Israel)
  • SANDOZ (Germany)
  • Intas (Ahmedabad)
  • Gyjtrs (United States)
  • NANG KUANG (China)
  • Tianjin Kingyork (China)
  • Baxter (United States)
  • CSL (Australia)
Additional players considered in the study are as follows:
Grifols (Spain) , Octapharma (Switzerland) , CBOP (Mumbai)
Select User Access Type

Key Highlights of Report


Jan 2024 209 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neuromyelitis Optica Drug Quantitative research analysis
Global Neuromyelitis Optica Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (Germany), FRESENIUS (United States), TEVA (Israel), SANDOZ (Germany), Intas (Ahmedabad), Gyjtrs (United States), NANG KUANG (China), Tianjin Kingyork (China), Baxter (United States) and CSL (Australia) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of Nano Technology in Neuromyelitis Optica Drug " is seen as one of major influencing trends for Neuromyelitis Optica Drug Market during projected period 2023-2030.
The Neuromyelitis Optica Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Neuromyelitis Optica Drug Report?

Have a Query? Click Here

Other Related Reports

Protein Therapeutic Comprehensive Study by Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), Application (Cancer, ...
$ 3750
Pet Ear Care Products Comprehensive Study by Type (Ear Cleansing Solution (Medicated, OTC (Over the Counter)), Ear Cleaner Wipes, Others), Application (Dogs, Cats, Others), Sales Channel (Online Sale...
$ 3500
Undegradable Protein Comprehensive Study by Type (Plant-based, Animal Based), Application (Aquaculture, Others), Distribution Channel (Online Sales Channel, Offline Sales Channel) Players and Region ...
$ 3500
Montelukast API Comprehensive Study by Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline), Application (Asthma,, Allergic Rhinitis, Bronchospasm, Urticaria, Others), Dosage Form (Tab...
$ 3350
Drug & Pharmaceuticals & Cosmetics Retail Comprehensive Study by Type (Cosmetic, Pharmaceutical), Application (Child, Women, Men), Channel (Direct Sales, Distribution Channel) Players and Region - Gl...
$ 3400
Immune Boosting Supplement Comprehensive Study by Type (Vitamin C Supplements, Vitamin D Supplements, Vitamin B Supplements, Selenium Supplements, Zinc Supplements, Herbal Supplements, Probiotic Supp...
$ 3800